A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...

A new drug called ivonescimab just beat standard immunotherapy in a major lung cancer trial: patients lived nearly four ...

What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...